Skip Navigation

Research Funding

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

June 2013 DMID Council-Approved Concepts

Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Partnerships for the Development of Diagnostics for Biodefense

For the published request for applications, see the March 12, 2014, Guide announcement, Partnerships for Diagnostics to Address Antimicrobial Resistance of Select Bacterial Pathogens (R01).

Partnerships for the Development of Novel Therapeutics for Selected Pathogens

Request for Applications (R21/R33)

Contact: Michael Schaefer

Objective: To stimulate innovation in the discovery and development of novel therapies for infections caused by resistant gram-negative bacteria and multiple subtypes of influenza A, including drug resistant influenza.

Description: This initiative seeks to stimulate innovation in the discovery and development of novel therapies for infections caused by selected resistant pathogens of significant clinical concern. Examples of areas to be supported related to bacterial pathogens include novel approaches to exploit bacterial transport mechanisms to facilitate the uptake of anti-gram-negative small molecules; developing efflux pump blockers; discovering novel compounds to protect antibacterials from bacterial enzymatic modification and destruction; novel approaches to combat porin downregulation; developing biofilm inhibitors to render bacteria more susceptible to antibacterials; and developing inhibitors of the bacterial stress response system to prevent upregulation of resistance genes in response to antibacterial agents. In addition, agents directed towards unexploited gram-negative targets as well as novel members of existing classes of approved antibacterials with substantially improved resistance profiles are eligible. Projects must focus on novel treatment strategies for gram-negative pathogens where antimicrobial resistance threatens effective treatment, including Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, pathogenic Escherichia coli, and Neisseria gonorrhoeae.

Examples of areas to be supported related to influenza include discovering and developing novel viral or host-targeted small molecule-based interventions, including compounds that modulate the immune response or target host factors involved in the viral life cycle; optimizing antiviral candidates with oral bioavailability and a novel mechanism of action (different from neuraminidase inhibition); and identifying and validating new drug targets on the virus or host.

Partnerships for the Development of Novel Therapeutics for Select Anaerobic Protozoa

Request for Applications (R21/R33)

Contact: Michael Schaefer

Objective: To encourage the translation of basic research findings for developing effective treatments for human infections caused by anaerobic protozoa such as Giardia lamblia, Entamoeba histolytica and related free-living species of amoeba, and Trichomonas vaginalis.

Description: This initiative encourages developing novel interventions for treating infectious diseases of humans caused by anaerobic protozoa (e.g., amebiasis, giardiasis, and trichomoniasis). Projects eligible for funding under this initiative would include developing small molecule inhibitors and adjunctive therapeutics targeting resistance mechanisms.

Early stage translational and/or preclinical projects might include:

  • Identifying drug targets and drug candidates that are effective on the cyst form (where relevant).
  • Studying mechanism(s) of action and mechanism(s) of resistance to inform the development of novel interventions.
  • Identifying drug candidates with a superior profile to existing therapies (e.g., potency, safety, and efficacy against resistant strains).
  • Studying novel formulations or combinations with a superior profile to existing therapies.
  • Identifying drug candidates with a broad spectrum of activity against anaerobic protozoa.
  • Identifying host factors for the development of interventions.

International Research in ID and AIDS (IRID-A)

For the published program announcement identifying location of peer review, see the January 30, 2014, Guide announcement, International Research in Infectious Diseases, Including AIDS (R01).

International Collaborations in Infectious Diseases Research (ICIDR)

For the published requests for applications, see the November 27, 2013, Guide announcements, International Collaborations in Infectious Diseases Research (U01) and International Collaborations in Infectious Diseases Research (U19).​

Last Updated March 13, 2014

Last Reviewed March 13, 2014